PPH logo

VanEck Vectors Pharmaceutical ETF (PPH)

$121.59

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PPH

AUM

$1.11B

P/E ratio

31.3

Dividend yield

1.8301%

Expense ratio

0.36%

Beta

0.433878

Price on PPH

Previous close

$122.65

Today's open

$123.40

Day's range

$121.44 - $124.17

52 week range

$97.52 - $124.17

Profile about PPH

show more

Headquarters

US

Exchange

NASDAQ Global Market

Issue type

Exchange-Traded Fund

PPH industries and sectors

Industries

Health

News on PPH

Which Healthcare ETF Is the Better Buy: VanEck's Pharma Fund PPH or iShares' Biotech Fund IBB?

VanEck Pharmaceutical ETF offers a lower expense ratio and a higher dividend yield than iShares Biotechnology ETF. iShares Biotechnology ETF provides broader exposure with over 200 holdings, while VanEck Pharmaceutical ETF concentrates on 26 pharmaceutical leaders.

news source

The Motley Fool • Nov 15, 2026

news preview

ETFs in Spotlight as FDA Vision Loss Warning Meets Lilly's Sleep Apnea Win

Eli Lilly's sleep apnea breakthrough amid the FDA's vision-loss warning puts diversified healthcare ETFs in the spotlight.

news source

Zacks Investment Research • Nov 11, 2026

news preview

Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF

VanEck Pharmaceutical ETF provides a higher dividend yield and lower price volatility compared to the State Street fund. State Street SPDR Pharmaceuticals ETF offers a more diversified portfolio with more than twice as many individual holdings.

news source

The Motley Fool • Oct 30, 2026

news preview

PPH: Key Pharmaceutical Innovations Support Bullish Outlook (Upgrade)

VanEck Pharmaceutical ETF is upgraded to Buy, driven by innovation in weight-loss treatments and robust product pipelines among top holdings. PPH's concentrated exposure to Eli Lilly, Merck, and Novo Nordisk provides key catalysts, with LLY's 49% revenue growth and novel obesity drugs leading the charge. Despite industry risks—pricing pressure, patent cliffs, and high R&D costs—PPH's top holdings are mitigating these through diversification and strong product pipelines.

news source

Seeking Alpha • Oct 29, 2026

news preview

Which Healthcare ETF Is the Better Buy: Simplify's Active PINK or VanEck's Pharma-Focused PPH?

Simplify Health Care ETF has a higher expense ratio and a lower dividend yield than VanEck Pharmaceutical ETF. VanEck Pharmaceutical ETF maintains a more concentrated portfolio focused exclusively on global pharmaceutical giants.

news source

The Motley Fool • Oct 11, 2026

news preview

Execution of Pharma Tariffs Brings These ETFs Into Focus

Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.

news source

Zacks Investment Research • Oct 6, 2026

news preview

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.

news source

Zacks Investment Research • Oct 5, 2026

news preview

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

The VanEck Pharmaceutical ETF offers a lower expense ratio of 0.36% compared to 0.58% for the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has delivered a higher 1-year total return of 41% relative to 31% for the VanEck fund.

news source

The Motley Fool • Oct 3, 2026

news preview

Should You Bet Big on Drugmakers? VanEck Pharmaceutical ETF vs.

The Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to 26 for the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF currently offers a significantly higher dividend yield and a lower expense ratio than its counterpart.

news source

The Motley Fool • Sep 11, 2026

news preview

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

news source

Zacks Investment Research • Sep 1, 2026

news preview

¹ Disclosures

Get started with M1

Invest in VanEck Vectors Pharmaceutical ETF

Open an M1 investment account to buy and sell VanEck Vectors Pharmaceutical ETF commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PPH on M1